Hair relaxer uterine cancer mass tort litigation is a sprawling federal lawsuit involving thousands of women who developed uterine cancer after using chemical hair straighteners. As of March 2026, nearly 15,000 cases have been filed in a multidistrict litigation (MDL) centralized in the Northern District of Illinois, making it the fourth-largest active MDL in the United States. The litigation centers on the allegation that manufacturers of popular hair relaxer brands—including L’Oréal, Revlon, SoftSheen-Carson, and others—failed to adequately warn consumers about the cancer risks associated with their products, despite growing scientific evidence linking frequent use to elevated uterine cancer risk. For example, a 52-year-old woman who used chemical relaxers every six to eight weeks for 25 years before developing uterine cancer at age 47 represents the typical plaintiff in this litigation.
She had no family history of cancer and no other risk factors that would explain her diagnosis. Her case, now consolidated with thousands of others, alleges that the manufacturers knew or should have known about the dangers but marketed their products without sufficient warnings to Black women, who purchase approximately 60 percent of all chemical straighteners sold in the United States while representing just 6.5 percent of the American population. This litigation is still in early stages. Science Day hearings began in January 2026 to establish expert evidence on causation, and Daubert hearings are scheduled for April 2026 to determine whether expert testimony will be admissible at trial. First bellwether trials—test cases that will help shape settlement negotiations—are expected in 2027, with potential settlements anticipated that same year if negotiations succeed.
Table of Contents
- THE SCIENTIFIC EVIDENCE LINKING CHEMICAL HAIR RELAXERS TO UTERINE CANCER
- HOW THE MASS TORT LITIGATION IS STRUCTURED AND WHERE CASES ARE BEING HEARD
- WHO IS MOST VULNERABLE TO HARM FROM CHEMICAL HAIR RELAXERS
- ELIGIBILITY REQUIREMENTS AND WHEN YOU CAN JOIN THE LITIGATION
- THE MAJOR DEFENDANTS AND PRODUCTS NAMED IN THE LITIGATION
- SETTLEMENT TIMELINE AND EXPECTED LITIGATION MILESTONES
- PROJECTED SETTLEMENT COMPENSATION AND CASE VALUATIONS
- Conclusion
THE SCIENTIFIC EVIDENCE LINKING CHEMICAL HAIR RELAXERS TO UTERINE CANCER
The scientific foundation for this litigation rests on several peer-reviewed studies conducted by reputable institutions. The national Institutes of Health (NIH) Sister Study, the most widely cited research, found that women who used chemical hair straighteners frequently had 2.55 times the risk of developing uterine cancer compared to women who never used such products. More strikingly, the NIH study estimated that while only 1.64 percent of non-users would develop uterine cancer by age 70, that risk jumped to 4.05 percent for frequent users—more than double the baseline risk. The Boston University School of Medicine’s Black Women’s Health Study, published in 2023, corroborated these findings with a focus on the population most affected by relaxer use. The study found that postmenopausal Black women who used relaxers more than twice yearly or for five or more years had over a 50 percent increased risk of uterine cancer.
This difference in risk between occasional and frequent users is significant: a woman using relaxers every three months for 20 years faces substantially different odds than someone who straightens her hair once or twice annually. The scientific evidence distinguishes between casual and heavy use, which is relevant to how individual cases may be valued in settlement negotiations. Beyond uterine cancer, researchers have identified associations between chemical hair relaxers and other malignancies, including pancreatic cancer, thyroid cancer, and non-Hodgkin’s lymphoma. However, uterine cancer remains the primary focus of the litigation because the evidence is strongest for this cancer type, and it is the disease most frequently diagnosed in plaintiffs who have filed suit. The limitation here is important: correlation between relaxer use and cancer risk does not definitively prove causation, which is why the Daubert hearings in April 2026 will be critical in determining whether plaintiffs’ expert witnesses can convince courts that the scientific evidence establishes a causal link.
HOW THE MASS TORT LITIGATION IS STRUCTURED AND WHERE CASES ARE BEING HEARD
All hair relaxer cancer cases have been consolidated into a single multidistrict litigation (MDL) in the U.S. District Court for the Northern District of Illinois, with Judge Mary M. Rowland presiding. As of March 2026, over 10,500 lawsuits are pending in this centralized litigation. Consolidating cases into an MDL allows for efficient management of scientific discovery and expert testimony, since all parties benefit from jointly developing evidence about whether the products cause cancer. Rather than litigating the same causation issues in 15,000 separate trials across the country, the MDL process streamlines the process through coordinated discovery and bellwether trials. The litigation follows a typical MDL structure: during the discovery phase, which is currently underway, both sides exchange documents, depose witnesses, and develop expert evidence. In January 2026, Science Day hearings began, where plaintiffs and defendants presented expert testimony on general causation—whether chemical relaxers can cause uterine cancer in women exposed to them.
By March 2, 2026, the deadline for general causation expert discovery passed, meaning both sides had to disclose which experts they would rely on. Following this, Daubert hearings scheduled for April 2026 will determine whether those experts can testify at trial or in settlement mediations. If the judge allows the expert testimony, settlement negotiations become more serious because defendants face greater trial risk. If the judge excludes key expert testimony, the reverse occurs. One important limitation to understand: being part of an MDL does not guarantee you will receive compensation. Cases must still satisfy eligibility requirements—you must have used the product, developed uterine cancer, and prove a reasonable timeline connecting your use to the disease. Additionally, the strength of individual cases varies based on how long you used the product, how frequently, and whether other risk factors for uterine cancer might apply. A woman who used relaxers heavily for 30 years may have a stronger case than one who used them occasionally for five years, and this distinction will likely be reflected in settlement valuations.
WHO IS MOST VULNERABLE TO HARM FROM CHEMICAL HAIR RELAXERS
Black women bear a disproportionate burden of risk from chemical hair relaxers. Research shows that Black women purchase 60 percent of all chemical straighteners sold in the United States, despite representing only 6.5 percent of the population. This disparity in use—driven by cultural factors around hair care and limited alternatives for achieving certain styling goals—means that Black women comprise the vast majority of plaintiffs in the uterine cancer litigation. Studies also show that Black women face higher baseline uterine cancer incidence rates compared to white women, making them particularly vulnerable to any additional risk factor that increases cancer odds. The Boston university research specifically examined risk among postmenopausal Black women, finding that those who used relaxers consistently over many years experienced significantly elevated cancer risk. However, the litigation includes women of all races, and some white and Hispanic women have also filed suit, particularly those who used relaxers heavily or started using them at a young age.
The age at which exposure begins matters: a woman who began using relaxers as a teenager and continued into her 40s or 50s had a longer window of exposure than someone who started in her 30s. For example, a plaintiff who used relaxers from age 15 to age 55—a 40-year exposure—may have a different risk profile and case valuation than a plaintiff with only 10 years of use. An important caveat: not every woman who used hair relaxers will develop uterine cancer, and not every woman who develops uterine cancer used relaxers. The epidemiological evidence shows an association and increased risk, but individual causation is harder to prove. This is why the litigation has been ongoing for years despite the available scientific studies. Defendants will argue that other factors—obesity, metabolic syndrome, hormonal treatments, reproductive history—better explain individual cases of uterine cancer. Plaintiffs must show that relaxer use was a material contributing factor, not just one of many possible causes.
ELIGIBILITY REQUIREMENTS AND WHEN YOU CAN JOIN THE LITIGATION
To pursue a claim in the hair relaxer uterine cancer litigation, you must generally satisfy four criteria: you must have used a chemical hair relaxer product manufactured by one of the named defendants, you must have been diagnosed with uterine cancer (including endometrial cancer, which is often classified interchangeably with uterine cancer), your cancer diagnosis must have occurred at a reasonable time following exposure to the product, and you must be able to establish that you used the product—ideally with some documentary evidence or medical records showing awareness of your relaxer use. Documentation is crucial. If you have medical records showing that a oncologist or gynecologist asked about your chemical relaxer use during your cancer diagnosis workup, that contemporaneous notation significantly strengthens your case. Similarly, if you have old receipts, beauty supply store loyalty cards, or testimony from friends and family about your long-term relaxer use, these documents help establish your exposure history. Without any evidence of relaxer use, your case becomes weaker because defendants will argue you cannot prove you actually used their product.
For example, a woman who has been a regular customer at a beauty supply store for 20 years but has no receipts may still have a viable claim if she can provide testimony from store employees who remember her purchases, or if her hairdresser or family members can attest to her consistent use. The timeline between exposure and diagnosis affects case valuations and admissibility. If you used relaxers for many years but did not develop cancer until decades later, that extended latency period is consistent with how cancer typically develops—as a disease process that unfolds over time. Conversely, if you used relaxers for only one year and developed cancer 40 years later, the temporal relationship is weaker. Most uterine cancer cases in the litigation involve women with five or more years of relaxer use and cancer diagnosed within 5 to 40 years of first exposure. If you believe you have a claim, consulting with an attorney who handles these cases is the best way to assess whether your exposure history and medical profile meet the standards for joining the litigation.
THE MAJOR DEFENDANTS AND PRODUCTS NAMED IN THE LITIGATION
The litigation names several major manufacturers and brands of chemical hair relaxers, including L’Oréal (a French multinational that owns multiple relaxer brands), Revlon, SoftSheen-Carson (owned by Strength of Nature), ORS Olive Oil, Just for Me, Motions, and Cantu. Some defendants have settled claims in other product liability litigation, while others are vigorously defending against the allegations. The defendants include both large multinational corporations and smaller specialty beauty companies. L’Oréal and Revlon, as major corporations with significant financial resources, are expected to bear most of the settlement burden if the litigation succeeds, though smaller manufacturers may also contribute. A key issue in the litigation is what defendants knew and when they knew it. Plaintiffs argue that manufacturers were aware of or should have been aware of cancer risks based on animal studies, consumer complaints, and medical literature before the NIH Sister Study was published in 2022.
The defendants counter that they relied on regulatory approvals from the FDA and that the scientific evidence was insufficient to warrant warnings about cancer risk until very recent years. This factual dispute—about the state of scientific knowledge at the time products were sold and what warnings were reasonable—is central to the litigation and will be litigated in the coming months. One important limitation: bankruptcy is always a concern in mass tort litigation. If a defendant becomes insolvent and files for bankruptcy protection, its liability may be limited or discharged, and victims may recover only a portion of their claimed damages. This happened in other product liability contexts, such as talc litigation where talc manufacturers faced bankruptcy filings. However, L’Oréal and Revlon remain solvent as of 2026, suggesting that settlements, if reached, have a better chance of being funded than in cases where defendant insolvency is a risk.
SETTLEMENT TIMELINE AND EXPECTED LITIGATION MILESTONES
The litigation timeline provides clarity on what to expect in the coming months and years. Science Day hearings began on January 8, 2026, and the deadline for general causation expert discovery passed on March 2, 2026. Daubert hearings are scheduled for April 2026, where judges will determine whether plaintiffs’ expert witnesses can testify about causation. These hearings are critical decision points: if experts are excluded, the litigation weakens substantially and may collapse. If experts are allowed to testify, the litigation strengthens and settlement negotiations intensify because defendants face greater trial risk. First bellwether trials are expected to begin in 2027. Bellwether cases are carefully selected representative cases that go to trial first, with juries determining liability and damages. The outcomes of bellwether trials provide valuable information about how juries view the evidence and what compensation levels they award.
Both sides use bellwether results to calibrate settlement discussions. If bellwether juries return large verdicts for plaintiffs, defendants typically become more motivated to settle. Conversely, if juries find in favor of defendants or award lower damages, settlements may become more difficult to achieve. Based on current timelines, realistic settlement payouts are projected to begin in 2027, though this depends heavily on how bellwether trials unfold. Ellen Reisman has been appointed as a special settlement mediator, suggesting that the parties are already contemplating settlement discussions even as litigation continues. Mediators work with both sides to bridge gaps and find common ground on settlement terms. Her involvement signals that by 2026 or early 2027, formal settlement negotiations are likely to accelerate. Settlement discussions often happen in parallel with trial preparations, and many cases ultimately settle rather than proceed to final judgment. If you are a plaintiff in this litigation, staying informed about settlement negotiations and bellwether trial results will help you understand how your individual case may be valued.
PROJECTED SETTLEMENT COMPENSATION AND CASE VALUATIONS
Settlement compensation in the hair relaxer litigation is projected to vary significantly based on case strength and individual circumstances. According to settlement evaluations being discussed by practitioners, average strong cases—involving clear documentation of relaxer use, substantial length of use (10+ years), and uterine cancer diagnosis with few competing risk factors—may be valued at approximately $300,000 on average. Weaker cases, involving limited use duration, unclear exposure, or significant competing risk factors like obesity or prior hormone therapy, may be valued at $150,000 or less. The most serious cases, involving permanent infertility or cases where cancer led to removal of reproductive organs and chronic complications, could exceed $1 million. These valuations are projections based on how similar mass tort litigation has settled in the past and on the current strength of scientific evidence.
They are not guaranteed outcomes. Actual settlement values will depend on several factors: the number of claimants ultimately determined to be eligible, the total compensation pool available (determined by defendants’ settlement offers and available insurance), how bellwether juries react to the evidence, and what percentage of cases are deemed eligible for compensation. If 10,000 eligible claimants participate but the settlement pool is only $2 billion, average compensation drops dramatically compared to a scenario where 5,000 claimants and a $3 billion settlement pool exist. For example, a woman who used L’Oréal relaxers three times monthly from age 20 to age 55, developed uterine cancer at age 60, had the cancer surgically removed but suffers from ongoing complications, and has extensive documentation of her product use and medical history might fall into the “strong case” category projected at $300,000 or higher. By contrast, a woman with only five years of relaxer use and uterine cancer diagnosed when she was 70, with significant other health conditions that might explain the cancer, would likely fall into the $150,000 or lower range. Individual circumstances vary enormously, which is why consulting with an attorney experienced in this specific litigation is advisable to understand how your case might be valued.
Conclusion
The hair relaxer uterine cancer mass tort litigation represents a significant challenge to manufacturers of chemical hair straighteners, with nearly 15,000 cases filed as of March 2026 in a centralized federal MDL in Illinois. The litigation is grounded in scientific evidence showing that frequent use of chemical relaxers substantially increases the risk of uterine cancer, particularly among Black women who are the primary consumers of these products. While the litigation is still in early stages with expert testimony hearings and bellwether trials anticipated in 2026 and 2027, settlement discussions are already underway, and realistic settlement payouts are projected to begin in 2027 if negotiations succeed.
If you used chemical hair relaxers and have been diagnosed with uterine cancer, you may be eligible to join this litigation and pursue compensation. Eligibility depends on your exposure history, your cancer diagnosis, and your ability to document that you used a product manufactured by one of the defendants. Settlement valuations are likely to range from under $150,000 to over $1 million depending on case strength, though individual outcomes will vary. Consulting with an attorney who specializes in mass tort litigation and has experience with the hair relaxer MDL is the best way to understand your rights and evaluate whether pursuing a claim aligns with your circumstances and goals.